Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

 Blogroll
Mylan Launches Generic Lipitor In Five European Countries

Mylan Launches Generic Lipitor In Five European Countries

May 11 2012 | comment(s)

PITTSBURGH and LYON, France, May 11, 2012 /PRNewswire/ -- Mylan Inc. today announced that it has launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg in France, Belgium, the UK, the Netherlands and Ireland. Mylan has received marketing authorization from each country's respective health authority to begin selling its product immediately. Atorvastatin Calcium is the generic version of Pfizer's Lipitor® Tablets. This product is indicated for the prevention of cardiovascular disease and hypercholesterolemia.

FDA Advisory Panel Recommends Approval Of Cameron Health's S-ICD® System For Patients At Risk Of Sudden Cardiac Arrest

FDA Advisory Panel Recommends Approval Of Cameron Health's S-ICD® System For Patients At Risk Of Sudden Cardiac Arrest

Apr 28 2012 | comment(s)

Pharmaxis Receives Approval To Market Bronchitol In The EU

Pharmaxis Receives Approval To Market Bronchitol In The EU

Apr 27 2012 | comment(s)

Alphabody Protein For Undruggable Extracellular And Intracellular Disease Targets

Alphabody Protein For Undruggable Extracellular And Intracellular Disease Targets

Apr 26 2012 | comment(s)

Alphabodies cross over the boundaries between biologics and small chemical drugs

Complix NV, a biopharmaceutical company focused on the discovery and development of Alphabodies, a class of protein therapeutics that are active against both extracellular and intracellular disease targets, announces that it will provide an update on new developments with its Alphabody(TM) platform at the Biologics Partnering Forum in Boston, MA on 29 April 2012.

Almost 50 Percent Of The Glaucoma Patient Population Remains Untreated, Signifying A Vast Market For Glaucoma Pharmaceuticals, Finds Frost & Sullivan

Almost 50 Percent Of The Glaucoma Patient Population Remains Untreated, Signifying A Vast Market For Glaucoma Pharmaceuticals, Finds Frost & Sullivan

Apr 26 2012 | comment(s)

Positive Top-Line Results From Phase 3 Study Of Ferric Citrate (Zerenex) In Japan

Positive Top-Line Results From Phase 3 Study Of Ferric Citrate (Zerenex) In Japan

Apr 23 2012 | comment(s)